SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-013051
Filing Date
2023-08-03
Accepted
2023-08-03 07:05:48
Documents
13
Period of Report
2023-07-28
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nbse-20230728x8k.htm   iXBRL 8-K 52385
2 EX-99.1 nbse-20230728xex99d1.htm EX-99.1 9495
  Complete submission text file 0001558370-23-013051.txt   185471

Data Files

Seq Description Document Type Size
3 EX-101.SCH nbse-20230728.xsd EX-101.SCH 3151
4 EX-101.LAB nbse-20230728_lab.xml EX-101.LAB 15263
5 EX-101.PRE nbse-20230728_pre.xml EX-101.PRE 9938
7 EXTRACTED XBRL INSTANCE DOCUMENT nbse-20230728x8k_htm.xml XML 4692
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

IRS No.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35963 | Film No.: 231138017
SIC: 2834 Pharmaceutical Preparations